Código 3001 (Harmonized System 2012 by 4 digits)
2024: US$41.6M, Total Trade Exchange
2024: US$11.2M, International Sales
2024: US$30.5M, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate was US$41.6M.
In 2024, the states with the most international sales in Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were Ciudad de México (US$1.43M), Jalisco (US$522k), Estado de México (US$109k), and Baja California (US$9.86k).
The states with the most international purchases in 2024 were Ciudad de México (US$10.6M), Jalisco (US$9.98M), Baja California (US$1.75M), Estado de México (US$1.01M), and Guanajuato (US$663k).
In 2024, the main commercial destinations of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were United States (US$662k), Japan (US$452k), Colombia (US$321k), Spain (US$156k), and Peru (US$153k).
The main commercial origins of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate in 2024 were United States (US$13M), China (US$7.77M), Brazil (US$2.25M), Costa Rica (US$418k), and Spain (US$279k).
In the global context, the main exporting countries of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate in 2022 were China (US$1.28B), United States (US$831M), and France (US$751M). In the same year, the main importing countries of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were France (US$1.14B), Singapore (US$658M), and United States (US$443M).
US$41.6M, Total Trade Exchange (2024)
In 2024, the total trade exchange of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate in Mexico (including international purchases and sales) was US$41.6M.
The visualizations show the net balance of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
April, 2025
In April 2025, international sales of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were US$192k, while international purchases reached US$2.33M. The above results in a trade balance of -US$2.13M.
2025-Q2: US$84.7k, International Sales
The visualization shows the quarterly concentration of international sales of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate at state level.
In the second quarter of 2025, international sales were US$84.7k, being the states with the most sales Ciudad de México (US$84.7k).
Ciudad de México: US$1.43M, State with the Most International Sales (2024)
United States: US$662k, Main commercial destination (2024)
In 2024, the states with the highest international sales in Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were Ciudad de México (US$1.43M), Jalisco (US$522k), Estado de México (US$109k), and Baja California (US$9.86k).
In 2024, the countries with the most international purchases from Mexico were United States (US$662k), Japan (US$452k), Colombia (US$321k), Spain (US$156k), and Peru (US$153k).
Ciudad de México: US$10.6M, State with the Most International Purchases (2024)
United States: US$13M, Main Commercial Origin (2024)
In 2024, the states with the highest international in Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were Ciudad de México (US$10.6M), Jalisco (US$9.98M), Baja California (US$1.75M), Estado de México (US$1.01M), and Guanajuato (US$663k).
The countries with the most international sales to Mexico in 2024 were United States (US$13M), China (US$7.77M), Brazil (US$2.25M), Costa Rica (US$418k), and Spain (US$279k).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were China (US$1.28B), United States (US$831M), and France (US$751M). In the same year, the main importing countries for Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were France (US$1.14B), Singapore (US$658M), and United States (US$443M).